Citation Impact
Citing Papers
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
The P450 Gene Superfamily: Recommended Nomenclature
1987
A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL
1999
Differential protease expression by cutaneous squamous and basal cell carcinomas.
1991
Urokinase Plasminogen Activator Is Immunocytochemically Detectable in Squamous Cell but Not Basal Cell Carcinomas
1992
T cell defined tumor antigens
1997
Prevention of cervical cancer through papillomavirus vaccination
2004
The role of urokinase-type plasminogen activator in aggressive tumor cell behavior
1990
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
2001
Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb
2000
Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes
1994
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system
1992
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia
2004
Plasminogen Activator Inhibitor-1 Is Expressed in Cultured Rat Sertoli Cells1
1998
Plasminogen‐activator inhibitor type 2 (PAI‐2) is a spontaneously polymerising SERPIN
1993
HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6
1999
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
1997
The plasminogen activator/plasmin system.
1991
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)
2004
Loss of Net as Repressor Leads to Constitutive Increased c-fos Transcription in Cervical Cancer Cells
2004 StandoutNobel
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
Viruses in human cancers
1999 StandoutNobel
Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation
1997
Immunolipoplexes: An Efficient, Nonviral Alternative for Transfection of Human Dendritic Cells with Potential for Clinical Vaccination
2005
Involvement of circadian clock gene Clock in diabetes‐induced circadian augmentation of plasminogen activator inhibitor‐1 (PAI‐1) expression in the mouse heart
2005
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma
1990
Chimeric Virus-like Particles of the Human Papillomavirus Type 16 (HPV 16) as a Prophylactic and Therapeutic Vaccine
1999
MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes
1998 Standout
Directed Plasminogen Activation at the Surface of Normal and Malignant Cells
1991
Proteolytic balance and capillary morphogenesis
1990
CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients
2007
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion
1994
The role of the E6-p53 interaction in the molecular pathogenesis of HPV
1999
Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates
1998
Pathophysiology of Premature Skin Aging Induced by Ultraviolet Light
1997 Standout
Towards patient‐specific tumor antigen selection for vaccination
2002
Cloning and characterization of hurpin (protease inhibitor 13): a new skin-specific, UV-repressible serine proteinase inhibitor of the ovalbumin serpin family
1999
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens
1997
Design and evaluation of antigen-specific vaccination strategies against cancer
2000
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
MHC ligands and peptide motifs: first listing
1995
Viruses in human cancers
1999 StandoutNobel
Papillomaviruses and cancer: from basic studies to clinical application
2002 StandoutNobel
Tumor Necrosis Factor-α Regulates Plasminogen Activator Inhibitor-1 in Rat Testicular Peritubular Cells*
1997
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia
1997
Immunohistochemical localization of the plasminogen activator inhibitor‐1 in breast cancer
1995
Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor
1994
Tissue Plasminogen Activator Contributes to the Late Phase of LTP and to Synaptic Growth in the Hippocampal Mossy Fiber Pathway
1998 StandoutNobel
The microenvironment of the tumour–host interface
2001 StandoutNature
Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex
1995
Type‐1 plasminogen activator inhibitor in human breast carcinomas
1992
Two Alternative Translation Mechanisms Are Responsible for the Expression of the HCV ARFP/F/Core+1 Coding Open Reading Frame
2003
Progress on new vaccine strategies against chronic viral infections
2004
Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of α2-macroglobulin receptor and urokinase receptor expression
1995
Structural basis of latency in plasminogen activator inhibitor-1
1992 Nature
An amino-acid taste receptor
2002 StandoutNature
An Antibody Fragment from a Phage Display Library Competes for Ligand Binding to the Low Density Lipoprotein Receptor Family and Inhibits Rhinovirus Infection
1995 StandoutNobel
A serpin‐induced extensive proteolytic susceptibility of urokinase‐type plasminogen activator implicates distortion of the proteinase substrate‐binding pocket and oxyanion hole in the serpin inhibitory mechanism
2001
Differentiation of Phagocytic Monocytes into Lymph Node Dendritic Cells In Vivo
1999 StandoutNobel
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein?based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia
2004
Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes
2000 StandoutNobel
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
MConfocal Fluorescence Microscopy of Urokinase Plasminogen Activator Receptor and Cathepsin D in Human MDA-MB-231 Breast Cancer Cells Migrating in Reconstituted Basement Membrane
1994
Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric scFvs blocks the E6-mediated degradation of cellular p53
1999
Transforming Growth Factor β in Tissue Fibrosis
1994 Standout
Vaccine and antibody-directed T cell tumour immunotherapy
2004
Cancer vaccines
1998
Therapeutic Vaccination for HPV Induced Cervical Cancers
2007
A matrix metalloproteinase expressed on the surface of invasive tumour cells
1994 StandoutNature
Biochemical and biological aspects of the plasminogen activation system
1990
The Tumor Suppressor Protein p16 and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring Lysine-less Proteins That Are Degraded by the Ubiquitin System
2004 StandoutNobel
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
1994
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas
1996
Vaccinia Virus-Related Events and Phenotypic Changes after Infection of Dendritic Cells Derived from Human Monocytes
2000
Specificity of Serine Proteinase/Serpin Complex Binding to Very‐Low‐Density Lipoprotein Receptor and α2‐Macroglobulin Receptor/Low‐Density‐Lipoprotein‐Receptor‐Related Protein
1997
Fully mobilizing host defense: Building better vaccines
1998
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness
1996
Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms™) and oil-in-water vaccines
1998
Inhibition of Papillomavirus Protein Function in Cervical Cancer Cells by Intrabody Targeting
2005 StandoutNobel
CLOCK deubiquitylation by USP8 inhibits CLK/CYC transcription in Drosophila
2012 StandoutNobel
Conformation of one- and two-chain high molecular weight urokinase analyzed by small-angle neutron scattering and vacuum ultraviolet circular dichroism
1991 StandoutNobel
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
1991
Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.
1991
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
2001 StandoutNobel
New Approaches to Immunotherapy for HPV Associated Cancers
2011
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Serpin Structure, Mechanism, and Function
2002 Standout
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
Functional rafts in cell membranes
1997 StandoutNature
Constitutive Activation of Toll-Mediated Antifungal Defense in Serpin-Deficient Drosophila
1999 StandoutScienceNobel
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
1993
Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator
1991
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Potential Immunocompetence of Proteolytic Fragments Produced by Proteasomes before Evolution of the Vertebrate Immune System
1997 StandoutNobel
Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins.
1993 Standout
Proposed three-dimensional structure for the cellular prion protein.
1994 StandoutNobel
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
2001 StandoutNobel
Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
1990
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
1991
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
1991
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
1995
The serpin superfamily of proteinase inhibitors: structure, function, and regulation.
1994
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.
1990
Therapeutic Vaccines for Chronic Infections
2004 Science
Urokinase-type plasminogen activator and malignancy
1993
Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts
1997
The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion
1994
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
1997 StandoutNobel
Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
1994 StandoutNobel
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
1990
Binding of urokinase-type plasminogen activator–plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor
1998
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
1995
Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion
2000 StandoutNobel
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
1990
Sertoli-Sertoli and Sertoli-Germ Cell Interactions and Their Significance in Germ Cell Movement in the Seminiferous Epithelium during Spermatogenesis
2004 Standout
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma
1994
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
1995
Matrix Metalloproteinases: A Review
1993 Standout
Progress on new vaccine strategies against chronic viral infections
2004
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
1994
Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study
1995
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination
2004
Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses
2005 StandoutNobel
The Urokinase Receptor. Protein Structure and Role in Plasminogen Activation and Cancer Invasion
1995
Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
1995
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
2001 StandoutNobel
Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules
2019 StandoutNobel
Works of Simon Stacey being referenced
Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif.
1994
Identification of a naturally processed HLA A0201‐restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein
1994
Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs)
1996
Induction of cytochrome P-450IA1 gene expression in human breast tumour cell lines
1988
Plasminogen activator inhibitors: hormonally regulated serpins
1990
Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity
2000
Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells
2001
Serological responses to HPV 16 in cervical dysplasia and neoplasia: Correlation of antibodies to E6 with cervical cancer
1993
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
1996
Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors
1999
Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame
1995
Adeno-Associated Virus Rep78 Protein Interacts with Protein Kinase A and Its Homolog PRKX and Inhibits CREB-Dependent Transcriptional Activation
1998
Human papillomavirus type 16 E6/E7‐specific cytotoxic T lymphocytes in women with cervical neoplasia
2000
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia
2000
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
2002
Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies.
1994
The E1∧E4 Protein of Human Papillomavirus Type 16 Associates with a Putative RNA Helicase through Sequences in Its C Terminus
2000
Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.
1988
Leaky Scanning Is the Predominant Mechanism for Translation of Human Papillomavirus Type 16 E7 Oncoprotein from E6/E7 Bicistronic mRNA
2000